Microcurrent therapy for dry age-related macular degeneration
Part of Eyes & vision clinical trials.
This trial tests a new type of electrical stimulation, called microcurrent therapy, to see if it can help people with a certain form of age-related macular degeneration (AMD) that is not the "wet" kind. The treatment is delivered through an eye patch-like device and may slow vision loss or improve function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have at least one large druse (a yellow deposit under the retina) larger than 125 microns due to AMD.
- Your best corrected vision in the study eye is between 20/40 and 20/200 (mild to moderate vision loss).
- You do not have any implanted electrical devices (like a pacemaker, cochlear implant, or deep brain stimulator).
- You do not have a metal implant within 20 cm of where the treatment electrode or grounding electrode will be placed.
- You have not had treatment with photobiomodulation (light therapy) or short-pulse laser in the past 12 months.
- You have not had any eye surgery (except cataract surgery) more than 3 months before screening, and you do not have a history of severe dry eye, glaucoma requiring multiple medications, or certain other eye conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new laser treatment (MacuTherm) for intermediate age-related macular degeneration (iAMD), an eye condition that affects central vision. The study aims to see if this treatment can slow or prevent progression to more advanced stages of the disease.
This study tests a light-based therapy called photobiomodulation for dry age-related macular degeneration (AMD). It aims to see if this treatment can help preserve vision in the dry AMD eye, and includes people who have dry AMD in one eye and wet AMD in the other.
This trial tests a new light-based treatment for intermediate age-related macular degeneration (AMD), a common eye condition that can lead to vision loss. The goal is to see if it is safe and helps slow down the disease.
This Phase 1 trial tests the safety and side effects of ASP7317 in older adults whose central vision is worsening from dry age-related macular degeneration (geographic atrophy). If you qualify, you would receive treatment in the study eye and be closely monitored for about a year.
This study tests an eye drop solution designed to treat wet age-related macular degeneration (AMD), a condition that causes blurry vision due to abnormal blood vessel growth. The treatment aims to reduce fluid and improve vision without the need for frequent eye injections.
This study is testing whether shining a special light on the eye, called photobiomodulation, can help people with dry age-related macular degeneration (AMD). If you have dry AMD and are willing to participate, you will receive the light treatment and be monitored.
Hear when a new Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.